N/A N=474 Randomized Single-blind Treatment

Proximal Effects of Alcohol on Same-Sex Intimate Partner Violence

Alcohol Consumption · Violence, Domestic · Stress, Psychological · Aggression

Bottom Line

View on ClinicalTrials.gov: NCT04625465 ↗

Enrolled (actual)

474

Serious AEs

0.2%

Results posted

Jul 2025

Primary outcome: Primary: Alcohol Use (Burst 1) — .45; .40; .41; .31 Proportion of reporting days

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: CBT Text Messaging (Behavioral); Attention Control Text Messaging (Behavioral)
Age: Adult, Older Adult · 21+ yrs
Sex: All
Sponsor: Georgia State University
Primary completion: Dec 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Alcohol Use (Burst 1)	.45; .40; .41; .31; .45; .41	—
PRIMARY Alcohol Use (Burst 2)	.49; .42; .41; .30; .42; .38	—
PRIMARY Alcohol Use (Burst 3)	.45; .41; .42; .35; .39; .39	—
PRIMARY Alcohol Use (Burst 4)	.45; .43; .41; .34; .40; .34	—
PRIMARY Intimate Partner Violence (IPV) Perpetration (Burst 1)	.019; .035; .031; .031; .017; .024	—
PRIMARY IPV Perpetration (Burst 2)	.047; .013; .015; .026; .018; .026	—
PRIMARY IPV Perpetration (Burst 3)	.042; .049; .018; .019; .015; .021	—
PRIMARY IPV Perpetration (Burst 4)	.042; .020; .017; .014; .045; .026	—
PRIMARY Alcohol Use --> IPV Perpetration (Pre-Intervention)	1.26; 1.32	.869
PRIMARY Alcohol Use --> IPV Perpetration (Post-Intervention)	1.48; 1.06	.210
SECONDARY Sexual Minority Stress (Burst 1)	.48; .54; .55; .59; .32; .42	—
SECONDARY Sexual Minority Stress (Burst 2)	.39; .32; .53; .42; .32; .36	—
SECONDARY Sexual Minority Stress (Burst 3)	.31; .29; .41; .42; .31; .30	—
SECONDARY Sexual Minority Stress (Burst 4)	.34; .37; .34; .32; .39; .33	—
SECONDARY Gender Minority Stress (Burst 1)	.80; .73; 1.17; 1.13; .73; 1.09	—
SECONDARY Gender Minority Stress (Burst 2)	.82; .64; 1.05; .73; .91; .95	—
SECONDARY Gender Minority Stress (Burst 3)	.50; .80; .77; .73; .73; .98	—
SECONDARY Gender Minority Stress (Burst 4)	.24; .46; .70; .41; .76; .93	—
SECONDARY COVID Stress (Burst 1)	1.88; 2.07; 1.81; 1.87; 1.61; 1.69	—
SECONDARY COVID Stress (Burst 2)	1.88; 2.07; 1.81; 1.88; 1.61; 1.69	—
SECONDARY COVID Stress (Burst 3)	2.20; 1.93; 1.80; 1.88; 1.64; 1.70	—
SECONDARY COVID Stress (Burst 4)	2.09; 2.00; 1.87; 1.82; 1.65; 1.65	—

Summary

We will recruit sexual and gender minority couples to complete 56 days of daily surveys in order to evaluate (1) the impact of COVID-19 stress and sexual and gender minority stress on heavy episodic drinking and intimate partner violence (IPV) perpetration, and (2) a brief, mobile-phone delivered text messaging intervention to mitigate the effects of these stressors. This project has high potential to inform how pandemic stress contributes to etiological models of alcohol-related IPV perpetration in sexual and gender minority couples and inform a culturally-sensitive, low burden, and easy to disseminate intervention to mitigate these effects critical during a pandemic when access to care is limited.

Eligibility Criteria

Inclusion Criteria (applies to both partners):

Both partners must identify as cisgender and sexual minority or at least one partner must identify as a gender minority (i.e., one's gender identity is non-congruent with their sex assigned at birth)
21 years or older
In an intimate relationship lasting at least one month in which there are at least 2 days of face-to-face contact each week
Consumption of 4 (assigned female at birth) or 5 (assigned male at birth) alcoholic drinks on at least three days in the past year

Exclusion Criteria

Seeking treatment or being in recovery for an alcohol or substance use disorder.
Endorsement of severe physical IPV (e.g., use of a weapon) in the past year.
Women who self-report that they are trying to get pregnant, that they are currently pregnant, or that they are currently breastfeeding .

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04625465). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.